FDAnews
www.fdanews.com/articles/174655-the-medicines-company-to-sell-hemostasis-products-to-mallinckrodt

The Medicines Company to Sell Hemostasis Products to Mallinckrodt

December 28, 2015

The Medicines Company is planning to sell its line of hemostasis products to Mallinckrodt Pharmaceuticals for up to $410 million as it aims to focus on core programs, including R&D for PCSK9 inhibition.

Three products, Recothrom, a recombinant topical thrombin; PreveLeak, a surgical sealant; and Raplixa, a powder fibrin sealant, are included in the deal.

Under a proposed agreement, The Medicines Company says it expects to receive an initial payment of about $175 million, including inventory. It also may receive up to $235 million in compensation for future milestone payments. The transaction is expected to close in the beginning of 2016.